全文获取类型
收费全文 | 35690篇 |
免费 | 2189篇 |
国内免费 | 160篇 |
专业分类
耳鼻咽喉 | 508篇 |
儿科学 | 829篇 |
妇产科学 | 635篇 |
基础医学 | 4239篇 |
口腔科学 | 657篇 |
临床医学 | 3456篇 |
内科学 | 8453篇 |
皮肤病学 | 414篇 |
神经病学 | 3452篇 |
特种医学 | 1434篇 |
外国民族医学 | 1篇 |
外科学 | 6234篇 |
综合类 | 222篇 |
一般理论 | 18篇 |
预防医学 | 2100篇 |
眼科学 | 477篇 |
药学 | 2041篇 |
中国医学 | 45篇 |
肿瘤学 | 2824篇 |
出版年
2023年 | 185篇 |
2022年 | 384篇 |
2021年 | 891篇 |
2020年 | 542篇 |
2019年 | 885篇 |
2018年 | 1093篇 |
2017年 | 754篇 |
2016年 | 771篇 |
2015年 | 925篇 |
2014年 | 1363篇 |
2013年 | 1839篇 |
2012年 | 2704篇 |
2011年 | 2896篇 |
2010年 | 1649篇 |
2009年 | 1584篇 |
2008年 | 2494篇 |
2007年 | 2636篇 |
2006年 | 2451篇 |
2005年 | 2374篇 |
2004年 | 2147篇 |
2003年 | 2006篇 |
2002年 | 1815篇 |
2001年 | 287篇 |
2000年 | 183篇 |
1999年 | 246篇 |
1998年 | 396篇 |
1997年 | 325篇 |
1996年 | 229篇 |
1995年 | 229篇 |
1994年 | 184篇 |
1993年 | 177篇 |
1992年 | 106篇 |
1991年 | 113篇 |
1990年 | 92篇 |
1989年 | 82篇 |
1988年 | 68篇 |
1987年 | 64篇 |
1986年 | 65篇 |
1985年 | 69篇 |
1984年 | 89篇 |
1983年 | 89篇 |
1982年 | 86篇 |
1981年 | 82篇 |
1980年 | 70篇 |
1979年 | 38篇 |
1978年 | 37篇 |
1977年 | 29篇 |
1976年 | 21篇 |
1975年 | 25篇 |
1974年 | 23篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Sokol H Beaugerie L Maynadié M Laharie D Dupas JL Flourié B Lerebours E Peyrin-Biroulet L Allez M Simon T Carrat F Brousse N;for the CESAME Study Group 《Inflammatory bowel diseases》2012,18(11):2063-2071
BACKGROUND: It remains to be shown whether inflammatory bowel disease (IBD) is associated with an increased risk of primary intestinal lymphoproliferative disorders (PILD). We assessed this risk in the CESAME French nationwide prospective observational cohort. METHODS: In all, 680 gastroenterologists enrolled 19,486 patients with IBD (Crohn's disease in 60.3%) from May 2004 to June 2005. Follow-up ended on 31 December 2007. Available biopsy samples and surgical specimens from patients with PILD (n = 14) were centralized for review. The reference incidence of PILD in the general population was obtained from the C?te d'Or registry and was used as a comparator to assess the standardized incidence ratio (SIR). The influence of thiopurine exposure was explored in a nested case-control study. RESULTS: In the CESAME population the crude incidence of PILD was 0.12/1000 patient-years, with a corresponding SIR of 17.51 (95% confidence interval [CI], 6.43-38.11; P < 0.0001). The risk was highest in patients exposed to thiopurines (SIR 49.52, 95% CI 13.49-126.8; P < 0.0001), while it did not reach statistical significance in patients na?ve to thiopurines (SIR 4.83, 95% CI, 0.12-26.91; P = 0.37). The odds ratio associated with ongoing thiopurine exposure (vs. na?ve) was 2.97 (95% CI, 0.30-infinity; P = 0.38). All 14 cases of PILD were non-Hodgkin's B-cell LD, 78.6% occurred in males, 85.7% arose in IBD lesions, and 45.5% were Epstein-Barr virus-positive. Eleven cases occurred in patients with Crohn's disease. Mean (SD) age at PILD diagnosis was 55.1 (5.6) years and the median time since IBD onset was 8.0 years (interquartile range, 3.0-15.8). CONCLUSIONS: Patients with IBD have an increased risk of developing PILD. (Inflamm Bowel Dis 2012;). 相似文献
992.
993.
Seegers J Vos MA Flevari P Willems R Sohns C Vollmann D Lüthje L Kremastinos DT Floré V Meine M Tuinenburg A Myles RC Simon D Brockm?ller J Friede T Hasenfu? G Lehnart SE Zabel M;EUTrigTreat Clinical Study Investigators 《Europace : European pacing, arrhythmias, and cardiac electrophysiology》2012,14(3):416-422
994.
995.
996.
997.
998.
Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure
999.
Herth FJ Noppen M Valipour A Leroy S Vergnon JM Ficker JH Egan JJ Gasparini S Agusti C Holmes-Higgin D Ernst A;International VENT Study Group 《The European respiratory journal》2012,39(6):1334-1342
The Endobronchial Valve for Emphysema Palliation Trial (VENT) was a multi-centre, prospective, randomised, controlled trial conducted to evaluate the safety and effectiveness of unilateral endobronchial valve (EBV) treatment. The purpose of this analysis was to assess outcomes in the previously unreported European VENT study cohort. Patients with advanced emphysema were randomly assigned (2:1) to receive Zephyr? (Pulmonx Inc., Redwood City, CA, USA) EBV treatment (n = 111) or medical management (n = 60). At 6 months, EBV patients demonstrated a significant improvement compared with the controls for mean ± SD change in forced expiratory volume in 1 s (7 ± 20% versus 0.5 ± 19%; p = 0.067), cycle ergometry (2 ± 14 W versus -3 ± 10 W; p = 0.04) and St George's Respiratory Questionnaire (-5 ± 14 points versus 0.3 ± 13 points; p = 0.047). At 12 months, the magnitude of the difference between groups for change from baseline was of similar magnitude to the differences seen at 6 months. Rates for complications did not differ significantly. EBV patients with computed tomography (CT) scans suggestive of complete fissure and lobar occlusion had a mean ± SD lobar volume reduction of -80 ± 30% and >50% met minimal clinical difference thresholds. The degree of emphysema heterogeneity did not preclude excellent outcomes. Unilateral lobar volume reduction using EBV treatment is safe and superior clinical results correlated with CT suggestive of complete fissures and successful lobar occlusion. Emphysema heterogeneity was not critical for determining positive outcomes. 相似文献
1000.